Pitfalls of using composite primary end points in the presence of competing risks

Journal of Clinical Oncology

Volumn 28, Issue 28, 2010, Pages 4297-4299

  Mell, Loren K ^a   Jeong, Jong Hyeon ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER THERAPY; EVENT FREE SURVIVAL; HIGH RISK PATIENT; MORTALITY; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK; SAMPLE SIZE; TREATMENT OUTCOME; BIOASSAY; COMPARATIVE EFFECTIVENESS; EDITORIAL; HUMAN; METHODOLOGY; NEOPLASM; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

COMPARATIVE EFFECTIVENESS RESEARCH; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; PROBABILITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK; SURVIVAL ANALYSIS;

EID: 78049445066     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.2802     Document Type: Note

References (39)

1. Tsiatis A: A nonidentifiability aspect of the problem of competing risks. Proc Natl Acad Sci U S A 72:20-22, 1975
2. Gelman R, Gelber R, Henderson IC, et al: Improved methodology for analyzing local and distant recurrence. J Clin Oncol 8:548-555, 1990
3. Pintilie M: Competing Risks: A Practical Perspective. Chichester, United Kingdom, John Wiley & Sons, 2006, pp 192-195
4. Latouche A, Porcher R: Sample size calculations in the presence of competing risks. Stat Med 26:5370-5380, 2007 (Pubitemid 351193567)
5. Freemantle N, Calvert M, Wood J, et al: Composite outcomes in randomized trials: Greater precision but with greater uncertainty? JAMA 289:2554-2559, 2003
6. Mell LK, Weichselbaum RR: More on cetuximab in head and neck cancer. N Engl J Med 357:2201-2202, 2007 (Pubitemid 350146125)
7. Smith RE, Colangelo L, Wieand HS, et al: Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst 96:1128-1132, 2004 (Pubitemid 39207048)
8. O'Sullivan B, Davis AM, Turcotte R, et al: Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial. Lancet 359:2235-2241, 2002 (Pubitemid 34717977)
9. Studer UE, Whelan P, Albrecht W, et al: Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24:1868-1876, 2006
10. Freidlin B, Korn EL: Testing treatment effects in the presence of competing risks. Stat Med 24:1703-1712, 2005 (Pubitemid 40754089)
11. Lefebvre JL, Ang KK, Larynx Preservation Consensus Panel: Larynx preservation clinical trial design: Key issues and recommendations-a consensus panel summary. Int J Radiat Oncol Biol Phys 73:1293-1303, 2009
12. Piccirillo JF, Costas I: The impact of comorbidity on outcomes. ORL J Otorhinolaryngol Relat Spec 66:180-185, 2004 (Pubitemid 39370454)
13. Schoenfeld DA: Sample-size formula for the proportional-hazards regression model. Biometrics 39:499-503, 1983
14. Latouche A, Porcher R, Chevret S: Sample size formula for proportional hazards modelling of competing risks. Stat Med 23:3263-3274, 2004 (Pubitemid 39462086)
15. Pintilie M: Competing Risks: A Practical Perspective. Chichester, United Kingdom, John Wiley & Sons, 2006, pp 115-126
16. Dignam JJ, Kocherginsky MN: Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 26:4027-4034, 2008
17. Punt CJ, Buyse M, Köhne CH, et al: Endpoints in adjuvant treatment trials: A systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 99:998-1003, 2007 (Pubitemid 47232601)
18. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
19. Pepe MS: Inference for events with dependent risks in multiple endpoint studies. J Am Stat Assoc 86:770-778, 1991
20. Gaynor JJ, Feuer EJ, Tan CC, et al: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88:400-409, 1993
21. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
22. Jeong JH, Fine JP: Parametric regression on cumulative incidence function. Biostatistics 8:184-196, 2007
23. Gooley TA, Leisenring W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18:695-706, 1999 (Pubitemid 29126745)
24. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley & Sons, 1980
25. Albertsen PC, Hanley JA, Gleason DF, et al: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975-980, 1998 (Pubitemid 28445095)
26. Sweat SD, Bergstralh EJ, Slezak J, et al: Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol 168:525-529, 2002 (Pubitemid 34793287)
27. Tsai HK, D'Amico AV, Sadetsky N, et al: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516-1524, 2007 (Pubitemid 351767235)
28. D'Amico AV, Denham JW, Crook J, et al: Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25:2420-2425, 2007 (Pubitemid 46999213)
29. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al: Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 25:4952-4960, 2007 (Pubitemid 350220427)
30. Chapman JA, Meng D, Shepherd L, et al: Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 100:252-260, 2008 (Pubitemid 351480540)
31. Tammemagi CM, Nerenz D, Neslund-Dudas C, et al: Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 294:1765-1772, 2005 (Pubitemid 41434622)
32. Mell LK, Dignam JJ, Salama JK, et al: Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol 28:15-20, 2010
33. Mell LK, Jeong J, Nichols MA, et al: Predictors of competing mortality in early breast cancer. Cancer (in press)
34. Kay R, Schumacher M: Unbiased assessment of treatment effects on disease recurrence and survival in clinical trials. Stat Med 2:41-58, 1983
35. Benichou J, Gail MH: Estimates of absolute cause-specific risk in cohort studies. Biometrics 46:813-826, 1990 (Pubitemid 20333612)
36. Korn EL, Dorey FJ: Applications of crude incidence curves. Stat Med 11:813-829, 1992
37. Pepe MS, Mori M: Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12:737-751, 1993
38. Machtay M, Glatstein E: "Just another statistic." Oncologist 3:iii-iv, 1998
39. Satagopan JM, Ben-Porat L, Berwick M, et al: A note on competing risks in survival data analysis. Br J Cancer 91:1229-1235, 2004 (Pubitemid 39424779)